MRK logo

Merck Stock Price

Symbol: NYSE:MRKMarket Cap: US$200.7bCategory: Pharmaceuticals & Biotech

MRK Share Price Performance

US$80.69
-33.86 (-29.56%)
19.6% undervalued intrinsic discount
US$100.41
Fair Value
US$80.69
-33.86 (-29.56%)
19.6% undervalued intrinsic discount
US$100.41
Fair Value
Price US$80.69
AnalystConsensusTarget US$100.41
WaneInvestmentHouse US$74.00
AscendedInvestor US$63.00

MRK Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$100.41 19.6% undervalued intrinsic discount

US Investments And New Product Launches Will Shape Future Markets

4users have liked this narrative
0users have commented on this narrative
313users have followed this narrative
WA
WaneInvestmentHouse
WaneInvestmentHouse·Updated
Fair Value US$74.00 9.0% overvalued intrinsic discount

Acqusition and awaiting analysis

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AS
AscendedInvestor·Updated
Fair Value US$63.00 28.1% overvalued intrinsic discount

(Hold) No pipeline Homerun to replace keytruda. But aggressively acquiring.

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent MRK News & Updates

No updates

Merck & Co., Inc. Key Details

US$63.6b

Revenue

US$14.4b

Cost of Revenue

US$49.2b

Gross Profit

US$32.8b

Other Expenses

US$16.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 30, 2025
Earnings per share (EPS)
6.57
Gross Margin
77.41%
Net Profit Margin
25.79%
Debt/Equity Ratio
72.2%

Merck & Co., Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About MRK

Founded
1891
Employees
74000
CEO
Robert Davis
WebsiteView website
www.merck.com

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and anti-PD-1 therapy, as well as KEYTRUDA (pembrolizumab) in patients with advanced solid tumors. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

U.S. Market Performance

  • 7 Days: 2.3%
  • 3 Months: 12.9%
  • 1 Year: 20.2%
  • Year to Date: 8.3%
The market has climbed 2.3% in the last 7 days, lead by the Information Technology sector with a gain of 4.1%. In the last year, the market has climbed 20%. Earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading